751
Participants
Start Date
September 30, 2004
Primary Completion Date
December 31, 2008
Study Completion Date
December 31, 2008
Docetaxel
Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
DOXIL
DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Hoover
Fountain Valley
Long Beach
Los Angeles
Palm Springs
Newark
Lakeland
Fort Gordon
Centralia
Joliet
Indianapolis
Lexington
Louisville
Lafayette
Baltimore
Jackson
Las Vegas
Newark
Albuquerque
Cooperstown
New York
The Bronx
Gastonia
Philadelphia
Upland
Providence
Charleston
North Charleston
Fort Worth
Pasadena
Plovdiv
Shumen
Sofia
Stara Zagora
Varna
Tartu
Rabat-les-Trois-Seigneurs
Tunis
Budapest
Debrecen
Szeged
Székesfehérvár
Zalaegerszeg
Ashkelon
Haifa
Jerusalem
Ramat Gan
Tel Aviv
Riga
Kaunas
Vilnius
Arnhem
Capelle aan den IJssel
Roosendaal
The Hague
Bialystok
Bydgoszcz
Bytom
Gdansk
Gdynia
Gliwice
Kielce
Koszalin
Krakow
Lodz
Lublin
Olsztyn
Poznan
Warsaw
Coimbra
Matosinhos Municipality
Bacau
Bucharest
Cluj-Napoca
Hunedoara
Iași
Onești
Timișoara
Arkhangelsk
Balashikha
Barnaul
Chelyabinsk
Engels Saratov Region
Irkutsk
Ivanovo
Izhevsk
Kazan'
Krasnodar
Leningrad Region
Lipetsk
Moscow
Moscow Region
Murmansk
Nizhny Novgorod
Novosibirsk
Obninsk
Omsk
Oryol
Petrozavodsk
Pyatigorsk
Rostov-on-Don
Ryazan
Saint Petersburg
Samara
Smolensk
Stavropol
Tomsk
Tver'
Ulyanovsk
Vladimir
Volgograd
Voronezh
Yaroslavl
Yekaterinburg
Belgrade
Kamenitz
Niš
Cape Town
Johannesburg
Kimberley
Parktown
Port Elizabeth
Pretoria
Pretoria Gauteng
Bilbao Vizcaya
Lleida
Madrid
Santander
Seville
Cherkassy
Chernivtsi
Dnipro
Donetsk
Kharkiv
Kiev
Luhansk
Lutsk
Odesa
Poltava
Simferopol
Uzhhorod
Vinnitsa
Zhytomyr
Huddersfield
Manchester
Nottingham
Sutton
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY